Earkart Limited participated in the world's largest otolaryngology conference in Indianapolis, USA from October 11-13, 2025. The company unveiled its next-generation OMNI platform, a remote diagnostic solution for ENT care. The event attracted over 5,000 ENT specialists, audiologists, and healthcare leaders from more than 75 countries. Earkart's booth featured live demonstrations of OMNI's real-time diagnostics and remote consultation capabilities. Multiple leading specialists expressed interest in adopting the platform after witnessing its capabilities. The company saw increased registration forms at their booth, indicating strong interest in the technology. OMNI is positioned for expansion in North America, Europe, the Middle East, and emerging healthcare markets. Earkart operates with 69% government and 29% private revenue, maintains 49 shop-in-shop clinics across 22 cities, and manufactures hearing aids under brands EQFY, Fame, and Radius.
Earkart Limited States No Price-Sensitive Information Behind Share Price Movement6 days ago
Earkart Limited responded to BSE's inquiry about significant movement in its share price, stating that the company has no information or announcements, including price-sensitive information, that may have influenced the price movement. The company confirmed it has made all necessary disclosures under SEBI regulations and will continue to do so when relevant events arise. Earkart attributed the share price movement to market-driven factors.